Zhang L, Zhang J, Zhang X, Liu S, Qi C, Gao S
Int J Mol Med. 2025; 55(4).
PMID: 40017111
PMC: 11875724.
DOI: 10.3892/ijmm.2025.5508.
Song Y, Kelava L, Kiss I
Int J Mol Sci. 2023; 24(17).
PMID: 37686110
PMC: 10487838.
DOI: 10.3390/ijms241713302.
Yan H, Tang S, Tang S, Zhang J, Guo H, Qin C
Front Pharmacol. 2022; 13:949566.
PMID: 36386184
PMC: 9640411.
DOI: 10.3389/fphar.2022.949566.
Blessing W, Digesu C, Liu R, Mahvi D, Tal-Mason A, Kumar A
Mol Cancer Ther. 2022; 21(11):1663-1673.
PMID: 36031342
PMC: 9633561.
DOI: 10.1158/1535-7163.MCT-21-0750.
Marima R, Francies F, Hull R, Molefi T, Oyomno M, Khanyile R
Biomedicines. 2021; 9(12).
PMID: 34944633
PMC: 8698559.
DOI: 10.3390/biomedicines9121818.
To study the role of pre-treatment microRNA (micro ribonucleic acid) expression as a predictor of response to chemoradiation in locally advanced carcinoma cervix.
Barik S, Mitra S, Suryavanshi M, Dewan A, Kaur I, Kumar D
Cancer Rep (Hoboken). 2021; 4(4):e1348.
PMID: 33660436
PMC: 8388174.
DOI: 10.1002/cnr2.1348.
MicroRNA miR-100 Decreases Glioblastoma Growth by Targeting SMARCA5 and ErbB3 in Tumor-Initiating Cells.
Alrfaei B, Clark P, Vemuganti R, Kuo J
Technol Cancer Res Treat. 2020; 19:1533033820960748.
PMID: 32945237
PMC: 7502994.
DOI: 10.1177/1533033820960748.
MicroRNAs in non-small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential.
Petrek H, Yu A
Pharmacol Res Perspect. 2019; 7(6):e00528.
PMID: 31859460
PMC: 6923806.
DOI: 10.1002/prp2.528.
Expression of miR-630 associated with tyrosine kinase inhibitor therapeutic response in lung adenocarcinoma cases.
Das S
J Thorac Dis. 2019; 11(Suppl 3):S253-S255.
PMID: 30997190
PMC: 6424790.
DOI: 10.21037/jtd.2019.01.92.
The role and mechanisms of action of microRNAs in cancer drug resistance.
Si W, Shen J, Zheng H, Fan W
Clin Epigenetics. 2019; 11(1):25.
PMID: 30744689
PMC: 6371621.
DOI: 10.1186/s13148-018-0587-8.
Differentially Expressed MicroRNAs in Conservatively Treated Nontraumatic Osteonecrosis Compared with Healthy Controls.
Wei B, Wei W, Wang L, Zhao B
Biomed Res Int. 2018; 2018:9015758.
PMID: 29977921
PMC: 5994295.
DOI: 10.1155/2018/9015758.
Pooling-analysis for diagnostic and prognostic value of MiRNA-100 in various cancers.
Dou Z, Lin S, Dai C, Lu Y, Tian T, Wang M
Oncotarget. 2017; 8(37):62703-62715.
PMID: 28977982
PMC: 5617542.
DOI: 10.18632/oncotarget.18697.
miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.
Florczuk M, Szpechcinski A, Chorostowska-Wynimko J
Target Oncol. 2017; 12(2):179-200.
PMID: 28243959
DOI: 10.1007/s11523-017-0478-5.
Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
Shi L, Xu Z, Wu G, Chen X, Huang Y, Wang Y
BMC Cancer. 2017; 17(1):138.
PMID: 28202053
PMC: 5312565.
DOI: 10.1186/s12885-017-3132-9.
Notch-1 Confers Chemoresistance in Lung Adenocarcinoma to Taxanes through AP-1/microRNA-451 Mediated Regulation of MDR-1.
Huang J, Chen Y, Li J, Zhang K, Chen J, Chen D
Mol Ther Nucleic Acids. 2016; 5(10):e375.
PMID: 27727250
PMC: 5095685.
DOI: 10.1038/mtna.2016.82.
Predicting MicroRNA Biomarkers for Cancer Using Phylogenetic Tree and Microarray Analysis.
Wang H
Int J Mol Sci. 2016; 17(5).
PMID: 27213352
PMC: 4881592.
DOI: 10.3390/ijms17050773.
Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Cristobal I, Rojo F, Madoz-Gurpide J, Garcia-Foncillas J
Mol Cell Biol. 2016; 36(12):1734-9.
PMID: 27090640
PMC: 4907099.
DOI: 10.1128/MCB.00130-16.
MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z
Oncotarget. 2016; 7(5):5702-14.
PMID: 26744318
PMC: 4868715.
DOI: 10.18632/oncotarget.6790.
microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance.
Naidu S, Garofalo M
Front Med (Lausanne). 2015; 2:77.
PMID: 26583081
PMC: 4631988.
DOI: 10.3389/fmed.2015.00077.
Overexpression of miR-100 inhibits cancer growth, migration, and chemosensitivity in human NSCLC cells through fibroblast growth factor receptor 3.
Luo J, Chen B, Ji X, Zhou S, Zheng D
Tumour Biol. 2015; 37:15517–15524.
PMID: 26314855
DOI: 10.1007/s13277-015-3850-z.